TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01322984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictures
Description: The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pictures
Description: The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Startle eliciting noise
Description: Startle will be elicited by 95 dB noise, presented at different times after picture onset.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Startle eliciting noise
Description: Startle will be elicited by 95 dB noise, presented at different times after picture onset.
Study: NCT04110119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)
Description: Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)
Description: Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Treatment
Description: High speed and low amplitude spinal manipulation techniques are applied to the case group.
Study: NCT00375219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years.
Study: NCT03606837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-617 PET/CT
Description: PET/CT Imaging with 68Ga-PSMA-617 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2 PET/CT
Description: PET/CT Imaging with 68Ga-RM2 injection
Study: NCT00633061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children \>2 months and 1.5 mg/kg every 12 hours for infants \<2 months. Duration of treatment is 6 weeks.
Study: NCT01162213

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lychee Fruit Extract
Description: placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lychee Fruit Extract
Description: placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lychee Fruit Extract
Description: placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lychee Fruit Extract
Description: placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
Study: NCT02141074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
Study: NCT02330783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg twice daily by oral of each 4-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400mg twice daily by oral of each 4-week cycle
Study: NCT01080677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine/propranolol combination tablet
Description: caffeine/propranolol combination tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine/propranolol combination tablet
Description: caffeine/propranolol combination tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match caffeine/propranolol combination tablet administered orally once daily
Study: NCT03097133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
Study: NCT01739153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention: CHEESE (High cheese intake)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention: MEAT (High Meat intake)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention: CARB (High Carbohydrate intake)
Study: NCT02292368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
Study: NCT01208688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Therapy
Description: Treatment group received functional electrical stimulation and control group received conventional occupational therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Therapy
Description: Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy
Description: The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
Study: NCT04039256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous ventricular restoration using heartech® device
Description: Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
Study: NCT03653533

Intervention type: DEVICE
Group type: OTHER
Intervention: MiniMed™ 640G
Description: The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin

Intervention type: DEVICE
Group type: OTHER
Intervention: MiniMed™ 640G
Description: The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin

Intervention type: DEVICE
Group type: OTHER
Intervention: MiniMed™ 640G
Description: The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin

Intervention type: DEVICE
Group type: OTHER
Intervention: Captor CGM Enlite®
Description: The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level

Intervention type: DEVICE
Group type: OTHER
Intervention: Captor CGM Enlite®
Description: The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level

Intervention type: DEVICE
Group type: OTHER
Intervention: SmartGuard®
Description: This SmartGuard® function is used to improve the glycemia stability in real condition
Study: NCT03608982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated patient
Description: The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No simulated patient
Description: Instead of a simulated patients, participants get to watch video clips on first aid techniques.
Study: NCT02447757

Intervention type: DRUG
Intervention: remifentanil
Description: Remifentanil analgesia during delivery
Study: NCT01473160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A contact lens
Description: CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
Study: NCT01474863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Citrulline
Description: Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W IV fluids at isovolumetric rate (about 15ml/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Citrulline
Description: Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
Study: NCT03231943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
Study: NCT02900534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based self-help
Description: 10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
Study: NCT00551902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with anterior chamber infusion system
Description: Trabeculectomy with anterior chamber infusion system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy without anterior chamber infusion system
Description: Standard trabeculectomy surgery
Study: NCT01306188

Intervention type: BIOLOGICAL
Intervention: Breast cancer cohort
Description: Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

Intervention type: BIOLOGICAL
Intervention: Lung cancer cohort
Description: Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.
Study: NCT05167123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light cured tri-calcium silicate base material
Description: TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light cured tri-calcium silicate base material
Description: TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
Study: NCT00583024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADENOVIRUS/PSA VACCINE
Description: 1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
Study: NCT02300909

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Decompression Surgery
Description: Lumbar Decompression Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Decompression Surgery
Description: Lumbar Decompression Surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdiscectomy Surgery
Description: Microdiscectomy Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdiscectomy Surgery
Description: Microdiscectomy Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydrated Human Amnion/Chorion Membrane (dHACM)
Description: Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
Study: NCT04201132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with Neuroguard IEP System
Description: Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
Study: NCT02827630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proteus Discover
Description: FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proteus Discover
Description: FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
Study: NCT00261313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: 6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aranesp
Description: If Hb drops below 110, 300mcg Aranesp will be administered.
Study: NCT01686854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (B)
Description: a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescriptive Diet (A)
Description: prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
Study: NCT02838069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection (2x106 ASC/5ml).
Description: Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection (10x106 ASC/5ml).
Description: Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
Study: NCT01177722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-Hep B-IPV vaccine
Description: 0.5 mL, Intramuscular
Study: NCT02870699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evonail
Description: film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evonail
Description: film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo excipient
Description: film forming excipient solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo excipient
Description: film forming excipient solution
Study: NCT03972007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotobiomodulation
Description: A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fotobiomodulation
Description: A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotobiomodulation
Description: A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fotobiomodulation
Description: A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.